Fruzaqla (Fruquintinib)

Inquire / Price
  • Model Number:
    RL23202402
  • Brand Name:
    Fruzaqla (爱优特)
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    7capsules/Box
  • Strength
    1mg,5mg
  • Compositon
    Fruquintinib (呋喹替尼)
  • Treatment
    Metastatic colorectal cancer
  • Form
    Capsule
  • Brand
    Fruzaqla (爱优特)
  • Quantity Unit
    (1mg&5mg)*7capsules/Box
  • Manufacturer
    HUTCHMED Biopharmaceutical Company,china

Fruquintinib (Fruzaqla)  sold under the brand name 爱优特 in china, is an oral, highly selective, small molecule VEGF receptor inhibitor. Because of the kinase selectivity of Fruzaqla, the risk of off-target toxicity is less than the risk with multikinase inhibitors, including regorafenib.

November 9, 2023, The FDA has approved fruquintinib (Fruzaqla) to treat adults with metastatic colorectal cancer who received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy for cases that are RAS wild-type and medically appropriate.


Link

Poster

Top